Amlodipine/atorvastatin/valsartan - HK inno.N
Alternative Names: Atorvastatin/amlodipine/valsartan; CJ 30061; IN-C008; Valsartan/atorvastatin/amlodipineLatest Information Update: 28 Nov 2022
At a glance
- Originator CJ HealthCare
- Developer HK inno.N
- Class Amides; Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Dihydropyridines; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P-450 enzyme system inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Hyperlipidaemia; Hypertension
Most Recent Events
- 28 Nov 2022 Amlodipine/atorvastatin/valsartan is still in preregistration for Hypertension in South Korea (HK inno.N pipeline, July 2022)
- 28 Sep 2020 Preregistration for Hyperlipidaemia in South Korea (PO) prior to September 2020 (HK inno.N pipeline, September 2020)
- 28 Sep 2020 Preregistration for Hypertension in South Korea (PO) prior to September 2020 (HK inno.N pipeline, September 2020)